Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 190

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 190
---
 agreed that Company would have a valuation of $[ ]. The Company board of directors also believed, after a thorough review of strategic alternatives and discussions with Company’s senior management and legal counsel, that the Merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Company, which would likely be a delisting of the Company’s Class A ordinary shares from Nasdaq if the Merger is not consummated]. After giving consideration to these and other factors, the Company board of directors approved the Merger, which the Company board of directors believes better positions Company for long -termsuccess. 96 DiamiR’s Reasons for the Merger DiamiR’s decision to proceed with the strategic combination with Aptorum Group, is based on the following considerations: •DiamiR Biosciences is a leader in microRNA (miRNA) biomarkers discovery and validation; DiamiR’s prospective biopharma services partners and customers are life sciences companies developing therapeutic treatments; Aptorum has accumulated significant knowledgebase in drug development processes and appreciates the importance of biomarkers as tools to quantify drug response, progression and target engagement; •Aptorum’s and DiamiR’s visions are aligned regarding combining therapeutic programs with accurate and minimally invasive biomarker panels for better patient outcomes; success in drug development is partly dependent on having the tools and technologies to recruit the “right” patient into clinical studies and to monitor drug response in study participants; DiamiR can help Aptorum develop and use a number of different diagnostic platforms to achieve this goal; DiamiR’s robust IP portfolio will allow this work to remain proprietary and gives the combined company an edge in the market place for such services; •DiamiR’s patent -protectedplatform technology has shown to be effective in detecting and differentiating neurodegenerative diseases, cancer, and inflammatory diseases; we believe there are synergies with Aptorum’s programs, in particular SACT -1drug repurposing program; •Aptorum and its executives have strong background in clinical services; DiamiR pursues dual business model of clinical testing and biopharma services; •DiamiR’s CLIA -certified, CAP -accreditedlaboratory is staffed with experienced assay development executives and staff with years of experience in developing molecular and biomarker testing solutions; this team validated and launched the first commercially available miRNA clinical test in oncology (thyroid cancer) and will apply their know -howto help Aptorum in its clinical development